跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
徐 千彝
副教授
,
心臟血管內科
主治醫師
,
臺北醫學大學附設醫院
成員
,
臺北醫學大學臺北心臟醫學研究中心
https://orcid.org/0000-0002-9493-7325
電子郵件
chienyihsu
tmu.edu
tw
,
161010
h.tmu.edu
tw
h-index
1598
引文
22
h-指數
按照存儲在普爾(Pure)的出版物數量及斯高帕斯(Scopus)引文計算。
2012
2024
每年研究成果
概覽
指紋
網路
專案
(5)
研究成果
(72)
資料集
(1)
類似的個人檔案
(11)
指紋
查看啟用 Chien-Yi Hsu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Activin A
21%
Acute Heart Infarction
52%
Albuminuria
21%
All Cause Mortality
15%
Angiotensin
21%
Angiotensin II
13%
Angiotensin Receptor
22%
Arteriosclerosis Obliterans
21%
Atrial Fibrillation
23%
Blood Pressure
21%
Carbon Monoxide
21%
Cardiogenic Shock
14%
Cardiology
62%
Cardiovascular Disease
26%
Cardiovascular System
45%
CHADS2 Score
21%
Chronic Kidney Disease
15%
Cohort Analysis
28%
Congestive Heart Failure
14%
Contrast-Induced Nephropathy
21%
Coronary Artery Disease
30%
Creatinine
17%
Cross Sectional Study
21%
Diabetes Mellitus
29%
Dipeptidyl Peptidase-4 Inhibitor
13%
Ejection Fraction
62%
Endothelial Cell
17%
Endothelial Progenitor Cell
43%
Enkephalinase Inhibitor
22%
Frailty
21%
Gelatinase B
15%
Hazard Ratio
25%
Health Care Cost
20%
Heart Failure
95%
Heart Failure with Reduced Ejection Fraction
29%
Heart Left Ventricle Ejection Fraction
18%
Heart Left Ventricle Failure
14%
Hypertension
21%
Intima-Media Thickness
21%
Leg Amputation
16%
Middle Age
21%
Myocardial Infarction
29%
Nephropathy
23%
Odds Ratio
15%
Percutaneous Coronary Intervention
14%
Reactive Oxygen Species
23%
Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase
21%
Sacubitril
43%
Serositis
18%
Valsartan
43%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Infarction
73%
All Cause Mortality
32%
Alzheimer's Disease
21%
Angiotensin
21%
Angiotensin II
14%
Angiotensin Receptor
22%
Angiotensin Receptor Antagonist
13%
Antiplatelet
17%
Atrial Fibrillation
32%
Brain Ischemia
20%
Carbon Monoxide
21%
Cardiovascular Disease
30%
Cardiovascular Risk
11%
Chronic Kidney Failure
15%
Cohort Study
44%
Combination Therapy
14%
Congestive Heart Failure
14%
Contrast Induced Nephropathy
21%
Coronary Artery Disease
28%
Diabetes Mellitus
23%
Dipeptidyl Peptidase IV Inhibitor
13%
End Stage Renal Disease
24%
Endothelial Dysfunction
14%
Endothelial Nitric Oxide Synthase
14%
Enkephalinase Inhibitor
22%
Frailty
10%
Gelatinase B
17%
Heart Failure
100%
Heart Failure with Reduced Ejection Fraction
28%
Heart Infarction
22%
Heart Ventricle Remodeling
21%
Hemodialysis
12%
Infection
10%
Inflammation
35%
Ivabradine
24%
Kidney Disease
12%
microRNA
21%
Mouse
14%
Myopathy
10%
New-Onset Atrial Fibrillation
10%
Nonischemic Cardiomyopathy
10%
Peripheral Occlusive Artery Disease
21%
Purinergic P2Y12 Receptor
10%
Reactive Oxygen Metabolite
12%
Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase
27%
Statin (Protein)
11%
Syndrome
12%
Toll Like Receptor
10%
Valsartan/Sacubitril
65%
Warfarin
21%